文献速递临床试验与 GCP基础与转化研究

美西律治疗非营养不良性肌强直:聚合N-of-1试验

Effect of Mexiletine on Muscle Stiffness in Patients With Nondystrophic Myotonia Evaluated Using Aggregated N-of-1 Trials.
PubMed 文献 · JAMA · 2018-01-01

本研究采用聚合N-of-1试验设计,在30例基因确诊的非营养不良性肌强直成人患者中评估美西律(600 mg/日)与安慰剂对日常肌强直的影响。结果显示美西律显著降低肌强直评分,效应与既往RCT一致;常见不良事件为胃肠道不适。

要点

  • 美西律600 mg/日可显著降低非营养不良性肌强直患者日常肌强直评分。
  • 聚合N-of-1试验在罕见病中可行,效应与既往RCT一致。
  • 胃肠道不适是最常见不良事件,需关注过敏反应等严重不良事件。

核心结论

  • 美西律可降低非营养不良性肌强直患者日常肌强直评分,效应与既往RCT一致。
  • 聚合N-of-1试验设计在部分慢性罕见病中评估干预可行。

研究设计与样本

  • 聚合、双盲、随机、安慰剂对照N-of-1试验,单中心学术转诊中心开展。
  • 筛查38例,纳入30例基因确诊的非营养不良性肌强直成人患者,27例完成,3例退出(1例因严重不良事件)。
  • 干预为美西律600 mg/日与安慰剂,多个4周治疗期。

主要发现

  • 27例完成者中24例发现临床有意义的治疗效应。
  • 贝叶斯分层模型显示,总体组和CLCN1亚组达到临床有意义肌强直降低的后验概率为100%,SCN4A亚组为93%。
  • 总体组肌强直评分基线中位数6.08(IQR 4.71-6.80),美西律期2.50(95%CrI 1.77-3.24),安慰剂期5.56(95%CrI 4.73-6.39);症状评分降低差值3.06(95%CrI 1.96-4.15;n=27), favoring 美西律。
  • 频率学派再分析显示,美西律较安慰剂平均降低日常肌强直3.12(95%CI 2.46-3.78),与既往RCT效应2.69(95%CI 2.12-3.26)一致。
  • 最常见不良事件为胃肠道不适(美西律21例[70%],安慰剂1例[3%]);严重不良事件1例(美西律[3%],过敏性皮肤反应)。

关键数值与推荐

  • 美西律600 mg/日,多个4周治疗期,与安慰剂对照。
  • 主要结局为日常肌强直评分(1-9分,分数越高损害越重),临床有意义效应定义为差值大于0.75分。

临床怎么用

  • 美西律600 mg/日可用于非营养不良性肌强直成人患者以降低日常肌强直。
  • 用药期间需监测胃肠道不适及过敏反应等不良事件。

局限性

  • 单中心学术转诊中心开展,样本量30例。
  • 3例退出研究,其中1例因严重不良事件退出。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In rare diseases it is difficult to achieve high-quality evidence of treatment efficacy because of small cohorts and clinical heterogeneity. With emerging treatments for rare diseases, innovative trial designs are needed. OBJECTIVE: To investigate the effectiveness of mexiletine in nondystrophic myotonia using an aggregated N-of-1 trials design and compare results between this innovative design and a previously conducted RCT. DESIGN, SETTING, AND PARTICIPANTS: A series of aggregated, double-blind, randomized, placebo-controlled N-of-1-trials, performed in a single academic referral center. Thirty Dutch adult patients with genetically confirmed nondystrophic myotonia (38 patients screened) were enrolled between February 2014 and June 2015. Follow-up was completed in September 2016. INTERVENTIONS: Mexiletine (600 mg daily) vs placebo during multiple treatment periods of 4 weeks. MAIN OUTCOMES AND MEASURES: Reduction in daily-reported muscle stiffness on a scale of 1 to 9, with higher scores indicating more impairment. A Bayesian hierarchical model aggregated individual N-of-1 trial data to determine the posterior probability of reaching a clinically meaningful effect of a greater than 0.75-point difference. RESULTS: Among 30 enrolled patients (mean age, 43.4 [SD, 15.24] years; 22% men; 19 CLCN1 and 11 SCN4A genotype), 27 completed the study and 3 dropped out (1 because of a serious adverse event). In 24 of the 27 completers, a clinically meaningful treatment effect was found. In the Bayesian hierarchical model, mexiletine resulted in a 100% posterior probability of reaching a clinically meaningful reduction in self-reported muscle stiffness for the nondystrophic myotonia group overall and the CLCN1 genotype subgroup and 93% posterior probability for the SCN4A genotype subgroup. In the total nondystrophic myotonia group, the median muscle stiffness score was 6.08 (interquartile range, 4.71-6.80) at baseline and was 2.50 (95% credible interval [CrI], 1.77-3.24) during the mexiletine period and 5.56 (95% CrI, 4.73-6.39) during the placebo period; difference in symptom score reduction, 3.06 (95% CrI, 1.96-4.15; n = 27) favoring mexiletine. The most common adverse event was gastrointestinal discomfort (21 mexiletine [70%], 1 placebo [3%]). One serious adverse event occurred (1 mexiletine [3%]; allergic skin reaction). Using frequentist reanalysis, mexiletine compared with placebo resulted in a mean reduction in daily-reported muscle stiffness of 3.12 (95% CI, 2.46-3.78), consistent with the previous RCT treatment effect of 2.69 (95% CI, 2.12-3.26). CONCLUSIONS AND RELEVANCE: In a series of N-of-1 trials of mexiletine vs placebo in patients with nondystrophic myotonia, there was a reduction in mean daily-reported muscle stiffness that was consistent with the treatment effect in a previous randomized clinical trial. These findings support the efficacy of mexiletine for treatment of nondystrophic myotonia as well as the feasibility of N-of-1 trials for assessing interventions in some chronic rare diseases. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02045667.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Stunnenberg BC, Raaphorst J, Groenewoud HM, et al. Effect of Mexiletine on Muscle Stiffness in Patients With Nondystrophic Myotonia Evaluated Using Aggregated N-of-1 Trials. JAMA. 2018. PMID: 30535218. doi:10.1001/jama.2018.18020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。